ArticleeLife2023
Antibodies to repeat-containing antigens in
Open access · goldFull text read
In one paragraph
Article in eLife, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
6.4field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 22 citations in OpenAlex.
- The Ratio of Immunogenicity: A quantitative metric to identify highly immunogenic protein antigens to improve tissue-engineered biomaterials.Biomaterials · 2026Article
- Antibody Responses to the ConservedPathogens (Basel, Switzerland) · 2026Article
- Conserved genetic and antigenic profiles of Pf12 and Pf41 in asymptomatic Plasmodium falciparum carriers in Tanzania.Scientific reports · 2026Article
- Integrated evaluation of antibody responses to mosquitoes and mosquito-borne pathogens using highly multiplexed serology.Science advances · 2026Article
- The N-terminal region of malaria vaccine candidate asparagine-rich merozoite antigen is immunodominant and targeted by polyreactive antibodies.Disease models & mechanisms · 2026Article
- PhIP-Seq: unveiling the complexity of antibody repertoires in health and disease.Frontiers in immunology · 2026Review
- Structural and functional insights from detailed computational analysis ofJournal of genetics · 2026Article
- The N-terminal region of malaria vaccine candidatebioRxiv : the preprint server for biology · 2025Article
- Controlled human malaria infection with NF54 and 7G8 strains elicit differential antibody responses to Plasmodium falciparum peptides.Frontiers in immunology · 2025Article
- Antibody responses in Burkinabe children againstFrontiers in immunology · 2025Article
- Serodynamics: A primer and synthetic review of methods for epidemiological inference using serological data.Epidemics · 2024Review
- Antibody-Dependent Respiratory Burst againstVaccines · 2024Article
- High heterogeneity of cross-reactive immunoglobulins in multiple sclerosis presumes combining of B-cell epitopes for diagnostics: a case-control study.Frontiers in immunology · 2024Article
- A candidate antibody drug for prevention of malaria.Nature medicine · 2024Article
- PhIP-Seq: methods, applications and challenges.Frontiers in bioinformatics · 2024Review
- Validation of a murine proteome-wide phage display library for identification of autoantibody specificities.JCI insight · 2023Article
- High-Throughput Antibody Profiling Identifies Targets of Protective Immunity againstBiomolecules · 2023Article
- A sting in the tail-are antibodies against the C-terminus of Plasmodium falciparum circumsporozoite protein protective?EMBO molecular medicine · 2023Article
- Novel antibody competition binding assay identifies distinct serological profiles associated with protection.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 3 countries.
Madhura RaghavanUniversity of California, San Francisco, San Francisco, United States.ORCID 0000-0002-8566-9189
Katrina L KalantarChan Zuckerberg Initiative, Redwood City, United States.
Elias DuarteUniversity of California, Berkeley, Berkeley, United States.ORCID 0000-0003-2541-5504
Noam TeyssierUniversity of California, San Francisco, San Francisco, United States.
Saki TakahashiUniversity of California, San Francisco, San Francisco, United States.
Andrew F KungUniversity of California, San Francisco, San Francisco, United States.
Jayant V RajanUniversity of California, San Francisco, San Francisco, United States.
John RekInfectious Diseases Research Collaboration, Kampala, Uganda.
Kevin K A TettehLondon School of Hygiene and Tropical Medicine, London, United Kingdom.
Chris DrakeleyLondon School of Hygiene and Tropical Medicine, London, United Kingdom.ORCID 0000-0003-4863-075X
Isaac SsewanyanaInfectious Diseases Research Collaboration, Kampala, Uganda.
Isabel Rodriguez-BarraquerUniversity of California, San Francisco, San Francisco, United States.ORCID 0000-0001-6784-1021
Bryan GreenhouseUniversity of California, San Francisco, San Francisco, United States.ORCID 0000-0003-0287-9111
Joseph L DeRisiUniversity of California, San Francisco, San Francisco, United States.ORCID 0000-0002-4611-9205
University of California, San Francisco · USLondon School of Hygiene & Tropical Medicine · GBChan Zuckerberg Initiative (United States) · USInfectious Diseases Research Collaboration · UGUniversity of California, Berkeley · US
Funding
BMI Bioinformatics Training GrantsT32GM067547 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HERNANDEZ, RYAN D. · 2003 to 2022
$6.6MNovel serologic assays of P. falciparum exposure for improved surveillance in control and elimination.R01AI119019 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GREENHOUSE, BRYAN R · 2016 to 2020
$2.7MUncovering the dynamics of human pathogens using high throughput multiplexed serological toolsR35GM138361 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI RODRÍGUEZ-BARRAQUER, ISABEL · 2020 to 2024
$1.6MMentoring translational scientists in international infectious disease researchK24AI144048 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Bryan R Greenhouse · 2019 to 2026
$1.6MNIAID NIH HHS K24 AI144048NIAID NIH HHS R01 AI119019NIGMS NIH HHS R35 GM138361NIGMS NIH HHS T32 GM067547NIH HHS A1089674 (East Africa ICEMR)NIH HHS AI119019NIH HHS AI144048
Abstract
Protection against
Indexed as
MalariaMalaria, FalciparumAdultAntibodies, ProtozoanAntigens, ProtozoanChildEpitopesHumansPlasmodium falciparumProtozoan ProteinsAntibodies, ProtozoanAntigens, ProtozoanEpitopesProtozoan Proteinsantibodiesantigen profilinghumanimmunologyinfectious diseaseinflammationmalariamicrobiologynatural immunityP. falciparumphage displayrepeat regions
Identifiers
What OpenQuestion holds
Textfull text, public
LicenceCC BY
reference markers read1
measurements read57
identifiers read7
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.